CS‑45™: Our Digital Platform for Patient Centric Research
A proprietary, real-time platform to collect high-quality patient insights in collaboration with patient associations.
CS-45™ generates valuable data in support of:
HEOR & Market Access department
Clinical and value dossiers to support pricing, reimbursement, and HTA submissions
Strategic Marketing & Positioning
Data-driven positioning, competitive insights, and value communication
Medical Affairs
Communication of clinical evidence for internal and external stakeholders
Governance & Policy
Patient insights to inform policy and healthcare planning and stakeholder engagement
Corporate Social Responsibility Patient centered evidence that support disease awareness and informed healthcare decision making
Use Cases:
Patient Insights & Preferences
Capture patient preferences on treatment attributes such as mode of administration, dosing frequency, and care setting
Understand treatment satisfaction and real-world patient experience
Quality of Life & Mental Health
Assess health-related quality of life across physical, emotional, and social domains
Evaluate mental health outcomes, including depression, anxiety, and overall psychological well-being
Measure symptom burden across key domains such as pain, fatigue, sleep, cognition, and emotional health
Capture disease-specific outcomes with sensitive and precise patient-reported measures
Functional Status & Daily Living
Assess patients’ ability to perform daily activities and overall functional status
Standardized & Comparable Outcomes
Collect patient-reported outcomes using validated approaches that enable comparability across studies and populations
Clinical Areas
Covers all clinical areas with established and organized patient associations, as listed below:
Cardiology
Cardiovascular & Metabolic Diseases
Oncology
Neurology
Immunology
Respiratory Diseases
Dermatology
Gastroenterology
Haematology, thrombosis and Haemostasis
Ophthalomology
ENT
Infectious Diseases & Vaccines
Rare Diseases
Patient Insights & Preferences
Objective
Understand patient preference trade-offs between efficacy, safety, and convenience to support launch positioning and lifecycle strategy.
Study Design
- Partner with MS patient associations in 2–3 EU countries
- Cross-sectional CS-45 survey (n≈200–400 patients)
- Modules:
- treatment attributes (route, frequency, monitoring burden)
- willingness to trade efficacy vs convenience
- prior treatment experience
Key Outputs
- % preference by treatment attribute (oral vs injectable vs infusion)
- quantified trade-offs (e.g., % accepting lower efficacy for oral option)
- segmentation (newly diagnosed vs experienced patients)
Pharma Value
- Medical Affairs: patient-centered narrative in scientific exchange
- Market Access: evidence supporting differentiated value beyond efficacy
- Brand Team: refined positioning and messaging
Quality of Life & Mental Health
Objective (Pharma)
Quantify the full patient burden of metastatic breast cancer (mBC), beyond survival endpoints, to support:
- value demonstration
- medical education
- patient-centric positioning
Study Design
- Collaboration with metastatic breast cancer patient associations (2–3 EU countries)
- Cross-sectional CS-45 survey (n≈150–300 patients)
- Instruments:
- EORTC QLQ-C30 (core cancer QoL)
- EORTC QLQ-BR23 (breast cancer module)
- PHQ-9 (depression)
- GAD-7 (anxiety)
- Additional modules:
- emotional distress related to disease progression
- treatment burden (hospital visits, side effects)
- impact on family and social roles
Key Outputs
- QoL scores across physical, emotional, and social domains
- % of patients with moderate/severe depression and anxiety
- correlation between treatment burden and QoL
- subgroup insights (line of therapy, age, time since diagnosis)
Pharma Value
- Medical Affairs
- Enables more patient-centered scientific communication
- Supports congress presentations and publications
- HEOR / Market Access
- Demonstrates burden beyond survival
- Strengthens arguments around value of improved tolerability and QoL
- Patient Engagement / Public Affairs
- Supports collaboration with advocacy groups
- Builds credibility around patient-centricity
Clinical & Symptom Outcomes
Objective (Pharma / Medical)
Characterize real-world symptom patterns to inform clinical development and medical strategy.
Study Design
- Partner with long COVID patient organizations
- Survey captures:
- fatigue, cognition, sleep, pain
- symptom persistence and variability
- n≈300–500 patients
Key Outputs
- prevalence and severity distribution of key symptoms
- identification of symptom clusters
- patient-reported impact over time
Pharma Value
- Clinical Development: prioritization of endpoints
- Medical Affairs: evidence for unmet need
- Pipeline Strategy: identification of target symptom domains
Functional Status & Daily Living
Objective (Pharma / HEOR)
Demonstrate the functional and economic burden of RA beyond clinical measures.
Study Design
- Collaboration with RA patient associations
- Instruments:
- HAQ (functional status)
- WPAI (work productivity)
- Additional questions:
- daily activity limitations
- caregiver dependence
Key Outputs
- % of patients with impaired work capacity
- absenteeism and presenteeism rates
- daily activity impairment scores
Pharma Value
- HEOR: inputs for cost-effectiveness models
- Market Access: supports reimbursement discussions
- Medical Affairs: broader disease burden narrative
Standardized & Comparable Outcomes
Objective (Pharma / Regional Medical)
Generate comparable, multi-country patient-reported evidence using a unified methodology.
Study Design
- Same CS-45 protocol deployed in 3–4 EU countries
- Use validated instrument (e.g., Haem-A-QoL)
- Consistent sampling via national patient associations
Key Outputs
- comparable QoL scores across countries
- differences in treatment satisfaction and access
- identification of regional disparities
Pharma Value
- Regional Medical Teams: aligned evidence base
- Market Access: country-specific insights within a common framework
- Global Strategy: supports harmonized messaging